Phase II randomised placebo-controlled trial of sodium selenate as a disease-modifying treatment in chronic drug-resistant temporal lobe epilepsy: the SeLECT study protocol

Introduction Epilepsy is one of the most common neurological conditions worldwide. Despite many antiseizure medications (ASMs) being available, up to one-third of patients do not achieve seizure control. Preclinical studies have shown treatment with sodium selenate to have a disease-modifying effect...

Descripció completa

Dades bibliogràfiques

Autors principals:	Lucy Vivash, Dennis Velakoulis, Patrick Carney, Patrick Kwan, Leonid Churilov, Terence J O’Brien, Christopher M Hovens, Nicholas Lawn, Piero Perucca, Sandy R Shultz, John-Paul Nicolo, Charles Malpas, Manori Wijayath, David Reutens, Hannah Johns, Sara MacPhail, Pablo Casillas-Espinosa, Chris Tailby, Lisa Gillinder
Format:	Artigo
Idioma:	Inglês
Publicat:	BMJ Publishing Group 2023-10-01
Col·lecció:	BMJ Open
Accés en línia:	https://bmjopen.bmj.com/content/13/10/e075888.full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!